Drug Therapy and Surgery in Congenital Heart Disease With Pulmonary Hypertension
Status:
Completed
Trial end date:
2020-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the hypothesis that treating PAH-CHD patients
preoperatively with PAH drugs and keeping them on treatment for six months after surgery
reduces the risk of immediate postoperative death and the risk of residual PAH at six months
following operation to <10%.
Phase:
N/A
Details
Lead Sponsor:
University of Sao Paulo General Hospital
Collaborators:
Fundação de Amparo à Pesquisa do Estado de São Paulo Instituto do Coracao